Literature DB >> 22723647

Development and refinement of a technique using a medical radiation therapy facility to irradiate immunodeficient mice bearing xenografted human tumours.

Marta Baro1, Lara I de Llobet, Ignasi Modolell, Ferran Guedea, Joana Visa, Josep Balart.   

Abstract

The need for using immunodeficient mice for xenoimplantation of tumours is increasing in translational research in radiation oncology. However, adverse effects of radiation and infectious diseases may ruin the experimental work, in particular when appropriate facilities are not available. In this report, we describe a procedure to deliver fractionated radiotherapy to xenoimplanted tumours in immunodeficient mice using a medical linear accelerator, a method that was devised as an alternative to the lack of facilities devoted to radiation research. The mice were irradiated under anaesthesia and aseptic conditions. Thirty Gray in 10 days using a 6 MV photon beam were delivered only to the right thigh of the mice where tumours were implanted. The mice were evaluated twice a week up to planned euthanasia. The follow-up of mice was completed without premature interruption due to toxicities or infectious diseases, an observation which demonstrates the feasibility of the method.

Entities:  

Mesh:

Year:  2012        PMID: 22723647     DOI: 10.1258/la.2012.011147

Source DB:  PubMed          Journal:  Lab Anim        ISSN: 0023-6772            Impact factor:   2.471


  4 in total

1.  Development and characterization of an isogenic cell line with a radioresistant phenotype.

Authors:  Lara I de Llobet; Marta Baro; Agnès Figueras; Ignasi Modolell; Maria V Da Silva; Purificación Muñoz; Arturo Navarro; Ricard Mesia; Josep Balart
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

2.  Anthropomorphic Phantoms for Confirmation of Linear Accelerator-Based Small Animal Irradiation.

Authors:  Julian R Perks; Steven Lucero; Arta M Monjazeb; Jian Jian Li
Journal:  Cureus       Date:  2015-03-05

3.  Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours.

Authors:  M Baro; L I de Llobet; A Figueras; I Skvortsova; R Mesia; J Balart
Journal:  Br J Cancer       Date:  2014-07-31       Impact factor: 7.640

4.  Simvastatin Enhances the Effects of Radiotherapy and Cetuximab on a Cell Line (FaDu) Derived from a Squamous Cell Carcinoma of Head and Neck.

Authors:  Lara I de Llobet; Marta Baro; Ricard Mesia; Josep Balart
Journal:  Transl Oncol       Date:  2014-03-05       Impact factor: 4.243

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.